Open-label Study of Liothyronine in MS

• Status: Completed
• Trial end date: 2017-09-18
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and tolerability of synthetic T3, liothyronine. It will establish if there are changes in MS symptoms and if there is a positive effect on markers of neuronal health.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University

Criteria

Inclusion Criteria:

• Must meet 2010 McDonald criteria for clinically definite MS

• Must be euthyroid

• Expanded Disability Status Scale (EDSS) 3.0-7.5

• Patients may be on MS immunomodulating therapies or immunosuppressant therapies during the study

Exclusion Criteria:

• Known thyroid disease (past or current)

• Currently on thyroid replacement therapy

• Steroid use within a month of screening

• History of coronary artery disease, atrial fibrillation, or other clinically significant cardiac disease

• History of adrenal insufficiency

• Ongoing renal and/or liver disease

• Ongoing severe depression and/or anxiety

• Use of carbamazepine, phenytoin, phenobarbital, warfarin, antacids, cholestyramine, colestipol, sucralfate, and rifampin

• Known contraindication to using beta-blocker medications

• History of alcohol or substance abuse in the past 6 months

• Pregnant or nursing

• If the investigator feels that participation in this study is not in the best interest of the subject